Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis

Eligibility Criteria

• * Subjects with previous traumatic lesion (tibial fracture, osteothomy) of the knee
• * Subjects with osteonecrosis
• * Subjects with meniscal surgery in the previous 6 weeks
• * Subjects with gout, hyperlipidemia
• * Subjects without decisional capacity
• * Subjects with inflammatory arthritis
• * Subjects with active infection
• * Subjects with any uncontrolled systemic disease
• * Subjects with a history of severe allergic/anaphylactic reactions or multiple allergies
• * Subjects planning to become pregnant, are pregnant, or are breast-feeding
• * Subjects with history or current evidence of drug or alcohol abuse within 36 months prior to screening visit
• * Subjects who have active autoimmune disease
• * Subjects who have coagulation disorders
• * Subjects who have received any other therapy, which, in the opinion of the investigator, could interfere with safety or efficacy evaluations
• * Subjects with current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study
• * Subjects with any other condition that, in the opinion of the investigator, makes the subject inappropriate to take part in this study
• * Subjects who have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs, e.g., aspirin, ibuprofen), or other substances known to increase coagulation time from 7 days pre- to 3 days post injection. A wash out period of 7 days is allowed
• * Subjects who have undergone immunosuppressive therapy, chemotherapy, biologics or systemic corticosteroids within 3 months prior to each study visit.
• * No intra-articular injection of corticosteroids within the last 24 weeks
• * No intra-articular injection of any other cellular therapy within the last 24 weeks